Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

July 22, 2023

Study Completion Date

July 22, 2023

Conditions

Allergic Conjunctivitis

Interventions

DRUG

Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%

combination ophthalmic solution

DRUG

Brimonidine Tartrate 0.025%

ophthalmic Solution

DRUG

Ketotifen Fumarate 0.035%

ophthalmic Solution

DRUG

Vehicle

ophthalmic Solution

Trial Locations (4)

114, Lynchburg

102, Memphis

103, Phoenix

101, Andover

All Listed Sponsors

lead

Bausch & Lomb Incorporated

INDUSTRY